James B. Breitmeyer - Jan 3, 2023 Form 4 Insider Report for Oncternal Therapeutics, Inc. (ONCT)

Role
Chief Executive Officer, Director
Signature
/s/Chase C. Leavitt, Attorney-in-fact
Stock symbol
ONCT
Transactions as of
Jan 3, 2023
Transactions value $
-$29,700
Form type
4
Date filed
1/5/2023, 05:00 PM
Previous filing
Aug 1, 2022
Next filing
Feb 24, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONCT Common Stock Tax liability -$28.3K -27.8K -4.88% $1.02 542K Jan 3, 2023 Direct F1
transaction ONCT Common Stock Tax liability -$1.35K -1.33K -5.25% $1.02 23.9K Jan 3, 2023 By Spouse F1
holding ONCT Common Stock 46.5K Jan 3, 2023 By Family Trust
holding ONCT Common Stock 733 Jan 3, 2023 By Child
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units.